Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

1.25EUR
5:06pm IST
Change (% chg)

€-0.05 (-3.70%)
Prev Close
€1.30
Open
€1.29
Day's High
€1.29
Day's Low
€1.21
Volume
84,746
Avg. Vol
122,036
52-wk High
€2.08
52-wk Low
€0.81

Latest Key Developments (Source: Significant Developments)

Transgene Receives $22.2 Million From Sale Of Part Of Its Stake In Tasly BioPharmaceuticals
Tuesday, 4 Aug 2020 

Aug 4 (Reuters) - TRANSGENE SA ::TRANSGENE RECEIVES $22.2 MILLION FROM THE SALE OF PART OF ITS MINORITY STAKE IN TASLY BIOPHARMACEUTICALS.FOLLOWING THIS SHARE SALE, TRANSGENE HOLDS 17.1 MILLION SHARES IN TASLY BIOPHARMACEUTICALS, EQUIVALENT TO 1.58% OF CHINESE COMPANY'S CAPITAL.TRANSGENE'S REMAINING SHAREHOLDING IN TASLY BIOPHARMACEUTICALS WOULD BE VALUED AT APPROXIMATELY $36.9 MILLION BASED ON PRICE OF CURRENT SHARE SALE.  Full Article

Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line
Monday, 4 May 2020 

May 4 (Reuters) - TRANSGENE SA ::VAXXEL ACQUIRES TRANSGENE'S DUCKCELT®-T17 CELL LINE TO DEVELOP INDUSTRIAL-SCALE VACCINES AGAINST RESPIRATORY VIRUSES.TRANSGENE BECOMES A SHAREHOLDER OF VAXXEL. DUCKCELT®-T17, INITIALLY DEVELOPED AND PATENTED BY TRANSGENE, IS AN AVIAN CELL LINE GROWN IN SUSPENSION.  Full Article

Transgene Says Coronavirus Crisis Might Impact Level Of Revenues From Collaborations
Friday, 3 Apr 2020 

April 3 (Reuters) - Transgene SA ::IMPACT OF COVID-19 AND CONTAINMENT MEASURES COULD CAUSE DISORGANIZATION OF CLINICAL SITES PARTICIPATING IN CLINICAL STUDIES, DELAY OR INABILITY TO PRODUCE DRUG CANDIDATES, EVEN TEMPORARY CLOSURE OF OUR ESTABLISHMENTS.ON CORONAVIRUS: COULD CAUSE DYSFUNCTION IN SUPPLY AND SHIPPING CHAIN ON WHICH COMPANY DEPENDS, LACK OF VISIBILITY IN SCIENTIFIC COMMUNITY DUE TO CANCELLATION OF INTERNATIONAL CONFERENCES.ON CORONAVIRUS: MATERIALIZATION OF RISKS WOULD HAVE A DOWNWARD IMPACT ON COMPANY'S ANTICIPATED LEVEL OF EXPENSES.ON CORONAVIRUS: MATERIALIZATION OF THESE RISKS WOULD ALSO HAVE A DOWNWARD IMPACT ON COMPANY'S ANTICIPATED LEVEL OF EXPECTED REVENUES FROM COLLABORATIONS.  Full Article

Transgene Receives Approval From ANSM To Initiate Two Clinical Trials
Monday, 16 Sep 2019 

Sept 16 (Reuters) - Transgene SA ::TRANSGENE RECEIVES APPROVAL FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE TWO CLINICAL TRIALS OF ITS LEAD MYVAC INDIVIDUALIZED IMMUNOTHERAPY TG4050.INTERNATIONAL PHASE 1 CLINICAL TRIALS EXPECTED TO START IN 2019.IN FRANCE, STUDIES WILL BE CONDUCTED AT INSTITUT CURIE AND TOULOUSE-ONCOPOLE.  Full Article

Transgene Updates On Phocus Study Of Pexa-Vec In Liver Cancer
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - TRANSGENE SA ::TRANSGENE PROVIDES AN UPDATE AFTER THE INTERIM FUTILITY ANALYSIS OF THE PHOCUS STUDY OF PEXA-VEC IN LIVER CANCER.TRANSGENE IS CONTINUING TO ADVANCE DEVELOPMENT OF ITS PROPRIETARY ONCOLYTIC VIRUSES, IN LINE WITH ITS STRATEGY.ARE OBVIOUSLY DISAPPOINTED WITH OUTCOME OF PHOCUS STUDY -CEO.WE ALSO EXPECT TO ANNOUNCE THE FIRST CLINICAL DATA WITH TG6002 IN PATIENTS WITH COLORECTAL CANCER LATER THIS YEAR. - CEO.WE EXPECT TO ANNOUNCE IMPORTANT CLINICAL RESULTS FROM OUR MOST ADVANCED THERAPEUTIC VACCINES; TG4010 IN LUNG CANCER AND TG4001 IN HPV-POSITIVE HEAD AND NECK CANCER.WITH FUNDING THROUGH TO 2022, CLEAR STRATEGY AND NOVEL TECHNOLOGY PLATFORMS SUCH AS INVIR.IO® AND MYVAC™, TRANSGENE IS WELL PLACED - CEO.  Full Article

Transgene Raises EUR 48.7 Million Gross In Rights Issue
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Transgene SA ::SUCCESS OF TRANSGENE’S €48.7 MILLION RIGHTS ISSUE.ISSUANCE OF 20,816,366 NEW SHARES AT A SUBSCRIPTION PRICE OF €2.34 PER NEW SHARE.TOTAL NET PROCEEDS OF THE RIGHTS ISSUE ARE EXPECTED TO BE AROUND €47.0 MILLION.  Full Article

Transgene Launches A Rights Issue For An Amount Of Up To 50 Million Euros
Friday, 14 Jun 2019 

June 14 (Reuters) - TRANSGENE SA ::LAUNCHES A RIGHTS ISSUE FOR AN AMOUNT OF UP TO €50 MILLION.SUBSCRIPTION RATIO: 1 NEW SHARE FOR 3 EXISTING SHARES.SUBSCRIPTION PRICE: €2.34 PER NEW SHARE.RIGHTS TRADING PERIOD: FROM JUNE 18, 2019 TO JUNE 25, 2019 (INCLUSIVE).SUBSCRIPTION PERIOD: FROM JUNE 20, 2019 TO JUNE 27, 2019 (INCLUSIVE).INSTITUT MÉRIEUX (THROUGH TSGH) HAS UNDERTAKEN TO SUBSCRIBE UP TO 75% OF THE NEW SHARES.DASSAULT BELGIQUE AVIATION HAS UNDERTAKEN TO SUBSCRIBE AT LEAST UP TO ITS CURRENT PARTICIPATION OF 4.7%.IF THE RIGHTS ISSUE IS REALISED ONLY UP TO 75%, THE COMPANY ESTIMATES THAT THE PROCEEDS OF THE TRANSACTION WOULD ENABLE IT TO MAINTAIN ITS CASH HORIZON THROUGH THE END OF 2021.  Full Article

Transgene Cash Position At End-Q1 9.1 Million Euros
Monday, 13 May 2019 

May 13 (Reuters) - TRANSGENE SA ::EUR 9.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019.KEY CLINICAL TRIALS CONFIRMED TO READOUT IN H2 2019.€20 MILLION REVOLVING CREDIT FACILITY SECURED WITH NATIXIS.TRANSGENE EXPECTS ITS CASH BURN FOR 2019 TO BE BETWEEN EUR 15 MILLION AND EUR 20 MILLION.Q1 OPERATING REVENUE EUR 1.9 MILLION VERSUS EUR 1.8 MILLION YEAR AGO.HAS EXTENDED ITS FINANCIAL VISIBILITY TO Q4 2020.CONFIRMS THAT IT EXPECTS READOUTS FROM ITS KEY CLINICAL TRIALS IN SECOND HALF OF 2019.  Full Article

Transgene Receives FDA Clearance To Commence Clinical Development In Ovarian Cancer For TG4050
Monday, 13 May 2019 

May 13 (Reuters) - TRANSGENE SA ::TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.RECEIVED INVESTIGATIONAL NEW DRUG (IND) CLEARANCE FROM FDA TO PROCEED WITH A PHASE 1 CLINICAL TRIAL OF ITS LEAD MYVAC™ CANDIDATE TG4050.PHASE 1 CLINICAL TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF TG4050 IN PATIENTS WITH OVARIAN, FALLOPIAN OR PERITONEAL SEROUS CELL CARCINOMA.STUDY, SPONSORED BY TRANSGENE, WILL BE CO-FINANCED BY TRANSGENE AND ITS PARTNER NEC.PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019.  Full Article

Transgene Secures A 20 Million Euros Revolving Credit Facility With Natixis
Monday, 18 Mar 2019 

March 18 (Reuters) - TRANSGENE SA ::TRANSGENE SECURES A €20 MILLION REVOLVING CREDIT FACILITY WITH NATIXIS.CREDIT FACILITY WILL HAVE A 30-MONTH TERM AND TRANSGENE WILL BE ABLE TO DRAW ON AND REPAY FACILITY AT ITS DISCRETION.CEO: "WITH THIS NEW LOAN FACILITY, WE NOW HAVE FUNDS NEEDED TO SUPPORT OUR CLINICAL AND PRE-CLINICAL ACTIVITIES UNTIL MID-2020".  Full Article

BRIEF-Transgene And Hypertrust Patient Data Care Announce Blockchain Solution For Clinical Trials Of Personalized Healthcare

* TRANSGENE AND HYPERTRUST PATIENT DATA CARE ANNOUNCE SUCCESSFUL GO-LIVE OF THE WORLD’S FIRST BLOCKCHAIN SOLUTION FOR CLINICAL TRIALS OF PERSONALIZED HEALTHCARE